康方生物涨超4%，自研古莫奇单抗第二项适应症获NDA受理，港股通创新药ETF涨近2%，近5日净流入超4.3亿元

动脉网01-23

1月23日，港股强势反攻，创新药纯度100%的港股通创新药ETF(159570)涨近2%，近5日净流入超4.3亿元，规模超251亿元同类领先。消息面上，康方生物自主研发的古莫奇单抗用于治疗活动性强直性脊柱炎的新药上市申请已获受理，有望为近400万患者带来新选择。此外，港股通创新药ETF标的指数权重股多数上涨，康方生物、科伦博泰生物-B涨超4%。2026年JPM大会落幕，中国创新药企大放异彩，凭借...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2605973400?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-23 11:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2605973400","market":"hk","top_or_hot":-1,"title":"康方生物涨超4%，自研古莫奇单抗第二项适应症获NDA受理，港股通创新药ETF涨近2%，近5日净流入超4.3亿元","media":"动脉网","content":"<div>\n<p>1月23日，港股强势反攻，创新药纯度100%的港股通创新药ETF(159570)涨近2%，近5日净流入超4.3亿元，规模超251亿元同类领先。消息面上，康方生物自主研发的古莫奇单抗用于治疗活动性强直性脊柱炎的新药上市申请已获受理，有望为近400万患者带来新选择。此外，港股通创新药ETF标的指数权重股多数上涨，康方生物、科伦博泰生物-B涨超4%。2026年JPM大会落幕，中国创新药企大放异彩，凭借...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123111011a44c58e2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康方生物涨超4%，自研古莫奇单抗第二项适应症获NDA受理，港股通创新药ETF涨近2%，近5日净流入超4.3亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康方生物涨超4%，自研古莫奇单抗第二项适应症获NDA受理，港股通创新药ETF涨近2%，近5日净流入超4.3亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-23 11:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123111011a44c58e2&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1月23日，港股强势反攻，创新药纯度100%的港股通创新药ETF(159570)涨近2%，近5日净流入超4.3亿元，规模超251亿元同类领先。消息面上，康方生物自主研发的古莫奇单抗用于治疗活动性强直性脊柱炎的新药上市申请已获受理，有望为近400万患者带来新选择。此外，港股通创新药ETF标的指数权重股多数上涨，康方生物、科伦博泰生物-B涨超4%。2026年JPM大会落幕，中国创新药企大放异彩，凭借...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123111011a44c58e2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0348784397.USD","symbol_name":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123111011a44c58e2&s=b","article_id":"2605973400","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123111011a44c58e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2605973400","pubTimestamp":1769137200,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"1月23日，港股强势反攻，创新药纯度100%的港股通创新药ETF涨近2%，近5日净流入超4.3亿元，规模超251亿元同类领先。消息面上，康方生物自主研发的古莫奇单抗用于治疗活动性强直性脊柱炎的新药上市申请已获受理，有望为近400万患者带来新选择。此外，港股通创新药ETF标的指数权重股多数上涨，康方生物、科伦博泰生物-B涨超4%。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","BK1574":"生物医药B类股","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","06990":"科伦博泰生物-B","09926":"康方生物","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1161":"生物科技","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC"},"translate_title":"Akeso Bio rose more than 4%, the second indication of self-developed gumokizumab was accepted by the NDA, the Hong Kong Stock Connect Innovative Drug ETF rose nearly 2%, and the net inflow in the past 5 days exceeded 430 million yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":0.9,"09926":1.5},"content_text":"1月23日，港股强势反攻，创新药纯度100%的港股通创新药ETF(159570)涨近2%，近5日净流入超4.3亿元，规模超251亿元同类领先。消息面上，康方生物自主研发的古莫奇单抗用于治疗活动性强直性脊柱炎的新药上市申请已获受理，有望为近400万患者带来新选择。此外，港股通创新药ETF标的指数权重股多数上涨，康方生物、科伦博泰生物-B涨超4%。2026年JPM大会落幕，中国创新药企大放异彩，凭借ADC、IO双抗、GLP-1等领域技术突破走向全球，部分实现细分领域突破。中国医药产业正站在全球化价值重估起点，2026年成验证转型成效关键节点，国内药企技术快速突破，全球化提速，呈现个体密集突破与板块整体性提速特征。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605973400","isCrawlerRequest":true}